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Abstract
The current/traditional human health risk assessment paradigm is challenged by recent scientiﬁc and
technical advances, and ethical demands. The current approach is considered too resource intensive, is not
always reliable, can raise issues of reproducibility, is mostly animal based and does not necessarily provide
an understanding of the underlying mechanisms of toxicity. From an ethical and scientiﬁc viewpoint, a
paradigm shift is required to deliver testing strategies that enable reliable, animal-free hazard and risk
assessments, which are based on a mechanistic understanding of chemical toxicity and make use of
exposure science and epidemiological data. This shift will require a new philosophy, new data,
multidisciplinary expertise and more ﬂexible regulations. Re-engineering of available data is also deemed
necessary as data should be accessible, readable, interpretable and usable. Dedicated training to build the
capacity in terms of expertise is necessary, together with practical resources allocated to education. The
dialogue between risk assessors, risk managers, academia and stakeholders should be promoted further to
understand scientiﬁc and societal needs. Genuine interest in taking risk assessment forward should drive
the change and should be supported by ﬂexible funding. This publication builds upon presentations made
and discussions held during the break-out session ‘Advancing risk assessment science – Human health’ at
EFSA’s third Scientiﬁc Conference ‘Science, Food and Society’ (Parma, Italy, 18–21 September 2018).
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1. Introduction
The current human health risk assessment is substantially hazard driven and based on world-wide
recognised protocols largely relying on animal studies. Translatability of results from these studies to
humans and considerations on the replacement, reduction and reﬁnement of animal studies are a
matter of debate. In parallel, biological and toxicological sciences today can beneﬁt from paramount
scientiﬁc and technological advances. In relation to hazard assessment, new tools are emerging that
enable a better understanding of the mechanisms leading to adverse effects, more accurate
predictions of biological responses and so help to establish causality, offering the beneﬁt of being, in
most cases, non-animal test models. Exposure science is also rapidly developing and epidemiological
research is facing a transition from empirical observations alone to a molecular epidemiology paradigm
incorporating exposure and pathogenesis. All these developments are promising and support a shift
from the current risk assessment paradigm to a more holistic approach, improving assessment of
human health risk while reducing animal testing.
A driver for this shift is the National Academies of Sciences, Engineering and Medicine (NASEM)
that, since 2007, has published reports providing a vision and a proposal for strategy for the toxicology
of the 21st century based on new tools and approaches, developing the exposure science and
proposing the integration of these tools to further advance risk assessments. These reports served as
the basis for various initiatives in the United States and world-wide accelerating data generation and,
in general, the effort for such a paradigm shift. Elaboration on the need/trend of a new conceptual
framework in human health risk assessment, supported by new concepts and tools in hazard
assessment and exposure has been proposed in the European Union (EU) in a SCHER/SCENIHR/SCCS
report in 2013.1
However, it is recognised that the implementation of new approaches and tools and the use of new
data generated face challenges impacting the paradigm shift, as well as acceptance by regulators.
Transparent and understandable communication of the strengths and weaknesses of new approaches
is pivotal to their application and acceptance by the scientiﬁc community, regulators and laypeople.
This publication is intended to present an overview of the general concepts at the basis of a
possible shift from traditional to holistic risk assessment and to apply the available relevant scientiﬁc
methodologies and technological advances that may entail such a shift, together with challenges and
needs, including:
• opportunities and challenges related to the application of new tools and technologies for the
identiﬁcation and characterisation of adverse effects;
• the role of human epidemiology in the identiﬁcation and characterisation of health effects
induced by chemicals;
• the integration of human biomarkers in exposure assessment.
While focusing on chemicals, many of the considerations discussed would be applicable to other
stressors.
Concrete case studies utilising new tools, new approaches for exposure assessment and their
integration are also presented.
This publication builds upon presentations made and discussions held during the break-out session
‘Advancing Risk Assessment Science – Human Health’ at EFSA’s third Scientiﬁc Conference ‘Science,
Food and Society’ (Parma, Italy, 18–21 September 2018). Additional discussions relevant to the topic
are presented in this issue by Cavalli et al. (2019), Hartung (2019) and Hougaard Bennekou (2019).
1.1. Advancing human health risk assessment – concepts
1.1.1. The NASEM reports envisioning the future of risk assessment:
opportunities and challenges
In 2007, the NASEM released the report ‘Toxicity testing in the 21st century: a vision and a
strategy’ (NRC, 2007), which capitalised on the advances in biology and related ﬁelds and increases in
computational power to envision a future in which toxicity testing primarily relies on high-throughput
in vitro assays and computational tools to assess potential adverse effects from chemical exposure. A
1 SCHER (Scientiﬁc Committee on Health and Environmental Risks), SCENHIR (Scientiﬁc Committee on Emerging and Newly
Identiﬁed Health Risks), SCCS (Scientiﬁc Committee on Consumer Safety), 2013. Addressing the New Challenges for Risk
Assessment. European Commission, ISSN 2315-0106 ISBN 987-92-79-31206-9 https://doi.org/10.2772/37863
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vision for exposure science was articulated several years later in the National Academies report,
‘Exposure science in the 21st century: a vision and a strategy’, (NRC, 2012), which expanded the
breadth and depth of exposure science given advances in, for example, monitoring technologies,
analytical techniques and computational tools. Since the release of those reports, various agencies and
organisations have started to collaborate within and outside the United States to advance the visions.
Generation of diverse data streams from government, industry and academic laboratories has
accelerated. Although scientists and others expect that implementation of the visions will take decades
to be fully achieved, the recent National Academies report, ‘Using 21st century science to improve risk-
related evaluations’ (National Academies of Sciences, Engineering, and Medicine, 2017), examines how
the data being generated today can be used in risk assessment applications. Four areas (priority
setting, chemical assessment, site-speciﬁc assessment and assessment of new chemicals) have been
identiﬁed that could beneﬁt from incorporating the 21st century science, and case studies have been
described. Although there are many technical issues still to be resolved, the report identiﬁed one
particular challenge that looms large. Technology has evolved far faster than our ability to analyse,
interpret and integrate the diverse, complex and large data streams for risk assessment. The path
forward to address the challenges entails a research agenda that develops, explores and documents
case studies capturing various scenarios of data availability for risk assessment applications.
Multidisciplinary collaboration will also be critical. Ultimately, application and acceptance of the new
approaches will depend on communicating the strengths and weaknesses in a transparent and
understandable way.
1.2. Holistic human health risk assessment: challenges to a ﬁt-for-
purpose approach
There is consensus that the 21st century paradigm shift in human health risk assessment will be
based on the understanding of mechanisms of toxicity rather than on the identiﬁcation of apical
endpoints of toxicity. This mechanistic shift has great potential for improving human health risk
assessment and tailoring it to different problem formulations. The transition to a mechanism-based risk
assessment of chemicals would require a holistic approach in which several aspects should be
considered: the identiﬁcation and use of adverse outcome pathway (AOP) as a framework that
integrates new approach methods (NAMs) supporting mechanistic understanding and predictive
screening; electronic data availability; rigorous analysis of uncertainties; deﬁnition of protection goals;
and ﬂexible and where necessary tailored data requirements, and harmonised approaches. A key
question is whether current EU regulations are ﬂexible enough to take full advantage of this potential.
In this context, several aspects should be considered:
• Are the standard requirements for risk assessment of human health ﬁt for purpose?
• Is there the need for more ﬂexibility in requirements and in the accompanying guidance
documents?
• Are existing data used at their best?
• Can mutual recognition of the risk assessment outputs be recognised?
This discussion is further developed in this issue by Hougaard Bennekou (2019).
1.3. New approach methods in toxicology for mechanism-based hazard
assessment
Many animal-based test methods have never been formally validated; their predictivity for complex
endpoints, such as cancer or developmental toxicity, is sometimes poor (60–70% range) and may for
speciﬁc cases (e.g. murine liver tumours) be questionable altogether. Moreover, interspecies
extrapolations are a large challenge. Animal-based testing, e.g. for developmental neurotoxicity (DNT),
is also extremely demanding in terms of resources. Finally, this approach has a low throughput and
yields little or no information on the mechanism of toxicity (Hartung and Leist, 2008; Leist and
Hartung, 2013; Daneshian et al., 2015; Meigs et al., 2018).
An alternative approach to animal testing, as suggested by the NASEM (Leist et al., 2008), and
large groups of scientists world-wide (Basketter et al., 2012; Ramirez et al., 2013; Leist et al., 2014,
2017; van Vliet et al., 2014; Gordon et al., 2015; Rovida et al., 2015; Marx et al., 2016) is the use of
combinations of in vitro (e.g. cell cultures, organoids, zebra ﬁsh embryos) and in silico (e.g. QSAR,
PBTK) methods. To distinguish these novel approaches for identiﬁcation and quantiﬁcation of chemical
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hazard from traditional animal experiments, they have been called NAM. Notably, in some ﬁelds, the
term NAM is used with a more extended scope to also include new types of animal studies, or to
comprise the use of pre-existing animal data for known compounds in a read-across procedure to
predict safety/hazard of new compounds. However, the term is used in this paper to imply only animal-
free new approaches as pursued by the H2020 research project EU-ToxRisk (Daneshian et al., 2016).
To use NAMs in a regulatory context, a process and criteria to set out their readiness are essential.
The readiness evaluation extends the scope of classical method validation by allowing different (ﬁt-for-
purpose) readiness levels for various applications. The ﬁeld of DNT testing can serve to exemplify the
application of readiness criteria. The number of chemicals not tested for DNT, and the testing cost per
chemical are over-whelming for in vivo DNT testing. So, there is a need for inexpensive, high-
throughput NAM approaches, to obtain initial information on potential hazards, and to allow
prioritisation for further testing (Bal-Price et al., 2015, 2018; Aschner et al., 2017; Fritsche et al., 2017,
2018). Based on readiness criteria, a (semi)-quantitative analysis process was assembled on test
readiness of 17 NAMs with respect to various uses (e.g. prioritisation/screening, risk assessment). The
scoring results suggest that several assays are currently at high readiness levels. Therefore, DNT NAMs
may be assembled into an integrated approach to testing and assessment (IATA). Furthermore, NAM
development may be guided by knowledge of signalling pathways necessary for normal brain
development, DNT pathophysiology and relevant AOPs. There is, however, an educational need on all
sides to understand strengths and weaknesses of the new approaches (Kadereit et al., 2012; van
Thriel et al., 2012; Smirnova et al., 2014; Schmidt et al., 2016; Hartung et al., 2019).
1.4. Use of epidemiological studies for chemical risk assessment:
strengths and limitations
Chemical risk assessment should ideally be based on studies carried out under controlled
experimental conditions. However, for humans, such experiments cannot be performed for potentially
harmful substances. Although human observational studies can be used as an alternative, the time
needed to generate reliable results for new substances and methodological limitations have
traditionally hampered their use. For these reasons, procedures and regulatory framework for chemical
risk assessment have largely been driven by reliance on experimental studies in animals. The
limitations of that approach are uncertainties related to extrapolating ﬁndings from animals to humans
and use of doses that are usually far higher than those observed in humans. Although these limitations
can be partly reduced by use of safety factors, it is increasingly acknowledged that precision in risk
assessment can be improved by incorporating ﬁndings from human observational studies. Recent
advancements in analytical chemistry in terms of rapid method development, reduction in sample
volume and cost, as well as improved access to computerised health data have made human
observational studies of sufﬁcient quality more frequently available for risk assessors. Apart from
general limitations in terms of bias (including confounding), use of human studies compared with
animal studies is more complicated due to occurrence of other co-exposures and the fact that
unexposed individuals usually do not exist. The quality of the exposure assessment is crucial. The high
variability in term of susceptibility to chemical exposures and interaction with other lifestyle factors
means that results from different human studies can be conﬂicting. The current framework for
chemical risk assessment is generally not compatible with these complexities and compromises are
needed. A better understanding of strengths and weaknesses of traditional toxicological studies and
human observational studies is the key for further advancing the methodology for chemical risk
assessment.
1.5. Risk communication and how simple heuristics inﬂuence
laypeople’s risk perception
Among aspects to be considered facing this change in risk assessment paradigm, of utmost
relevance is the risk communication versus laypeople. The qualitative characteristics of a hazard, and
not relevant quantitative information, strongly inﬂuence laypeople’s risk perception. Recent research
(Siegrist and S€utterlin, 2017; Scott et al., 2018) has focused on the role of simple heuristics: natural is
good and synthetic is bad, for example, in people’s hazard evaluations. The results of such studies
indicate that not only the negative consequences of a hazard, but also whether the hazard is human-
made (e.g. glyphosate) or naturally occurring (e.g. Campylobacter) has a signiﬁcant inﬂuence on
people’s perceptions. Indeed, negative outcomes are perceived to be more severe if they are
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anthropogenic than if they stem from nature. Perceiving gene technology to be unnatural also seems
to be a signiﬁcant reason why the risks as well as the beneﬁts associated with this technology are
perceived differently when compared with the risks and beneﬁts associated with conventional breeding
technology. Another heuristic that people may apply when evaluating the healthiness of foods is that
the absence of certain substances implies the product is healthier. Therefore, products with ‘free from’
labels (e.g. free from palm oil, free from genetically modiﬁed (GM) organisms) are perceived to be
healthier than products without such labels. Biased decisions that result from people’s reliance on
simple heuristics have been observed in different contexts, and they may result in non-optimal
decisions being made. However, providing information to laypeople seems to have only a limited
impact on how hazards are perceived. This poses a challenge for risk communication intended to
change laypeople’s perceptions so that they will fall more in line with the best available scientiﬁc
evidence.
2. Advancing human health risk assessment – new tools, new
approaches in exposure assessment and examples of their
integration
2.1. New tools
2.1.1. NAMs for new chemical safety testing strategies: the EU-ToxRisk project
The large-scale EU-ToxRisk project (http://www.eu-toxrisk.eu/) is an integrated European ‘ﬂagship’
programme with the vision to establish a paradigm shift in toxicity testing and risk assessment for the
21st century by implementing mechanism-based integrated testing strategies using non-animal NAMs.
To accomplish this, the EU-ToxRisk project has united all relevant scientiﬁc disciplines covering in silico
QSAR modelling, cellular toxicology, bioinformatics and physiologically based pharmacokinetic (PBPK)
modelling. The project tests the integration of the different NAMs in various case studies, ultimately
establishing: (i) pragmatic, read-across procedures incorporating mechanistic and toxicokinetic (TK)
knowledge; and (ii) ab initio hazard and risk assessment strategies for chemicals with little background
information. The case studies are focused on repeated dose systemic toxicity (RDT) targeting either
liver, kidney, lung or nervous system toxicity, as well as developmental/reproduction toxicity. The
integration of the various NAMs in deﬁned case studies allows the assessment of the overall
applicability domain of these NAMs in chemical hazard and ultimate risk assessment. Case studies are
centred around AOPs and include, for example, the application of NAMs for the assessment of: (i)
microvesicular liver steatosis induced by valproic acid analogues; (ii) the prediction of teratogenic
effects of valproic acid analogues; and (iii) the application of NAMs to assess the AOP pathway related
to inhibition of the mitochondrial respiratory chain complex 1 of nigra striatal neurons leading to
parkinsonian motor deﬁcits. Importantly, the activities in the case studies are supported and guided by
both cosmetics, (agro)-chemical, pharma industry stakeholders as well as various European regulatory
authorities. The ﬁnal goal is to deliver testing strategies to enable reliable, animal-free hazard and risk
assessment of chemicals based on a mechanistic understanding of chemical toxicity.
2.1.2. Assessment of chemical mixture-induced developmental neurotoxicity
using human in vitro model
Chemicals that are known to trigger-speciﬁc DNT effects belong to different chemical classes
including industrial chemicals, persistent organic pollutants (POPs), metals and pesticides. They belong
to multiple regulatory silos related to food and food quality such as pesticides, food contact materials
and food additives, including ﬂavourings, colourings and preservatives. These examples illustrate that
common, similar or related toxic effects triggered by various chemicals may be differently regulated
and that the combined effects of these chemicals across different regulatory domains are not currently
considered. At the same time, it is well documented in the existing literature that ‘mixture effects’ can
be greater than effects triggered by the most potent single chemical in a mixture, and the mixture
effects may be additive, or in some cases even synergistic. Therefore, implementation of mixture risk
assessment (MRA) for DNT evaluation, is strongly advocated as infants and children are indisputably
co-exposed to more than one chemical at the time. Indeed, for example, breast milk has been found
to contain chemicals regulated as pesticides, along with those regulated as cosmetics (including UV
ﬁlters parabens, phthalates), together with POPs including polychlorinated biphenyls (PCBs), conﬁrming
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that simultaneous co-exposure to multiple chemicals occurs in babies and during pregnancy (Schlumpf
et al., 2010; de Cock et al., 2014). A challenge in evaluation of DNT effects induced by chemicals is
that the neurodevelopmental outcome depends not only on the kind of exposure (dose, duration) but
also on the developmental stage of the brain at the time of exposure.
Therefore, in this study, it was proposed to use a mixed culture of neuronal and glial cells derived
from human induced pluripotent stem cells as this in vitro model makes it possible to evaluate a
chemical impact on key neurodevelopmental processes (including cell proliferation, migration and
morphological/functional neuronal and glial differentiation) mimicking critical stages of human brain
development. Moreover, the applied in vitro assays were anchored to the selected neurodevelopmental
processes that overlapped with common key events identiﬁed in AOPs relevant to impairment of
learning and memory in children; this is the most frequent adverse outcome identiﬁed in the existing
DNT AOPs (Bal-Price and Meek, 2017). The effects of the selected compounds (administered as a
single chemical or in mixtures) were assessed on human neural precursor cells undergoing
differentiation to determine synergistic, antagonistic or additive effects on brain-derived neurotrophic
factor (BDNF) level, neurite outgrowth and synaptogenesis after short- (72 h) or long-term exposure
(14 days in vitro). The obtained data suggest that low, non-/cytotoxic concentrations, below lowest-
observed-effect concentrations (LOAECs) of single chemicals become neurotoxic in mixture, especially
for the chemicals working through a similar mode of action (MOA) and after 14 days of exposure.
2.1.3. The use of toxicogenomics in chemical risk assessment
‘Omics methods addressing the whole genome (genomics), the transcriptome (transcriptomics), the
proteome (proteomics) and the metabolome (metabolomics) were established to be substantial in
toxicological research over the past decade. Currently, the impact of the AOP concept that tries to link
adverse to molecular effects is the way forward to regulatory toxicology as proposed already by the
Organisation for Economic Co-operation and Development (OECD), WHO and others. In risk
assessment, however, ‘omics methods play a signiﬁcant role in hazard identiﬁcation, but not in risk
characterisation due to the lack of relevant quantitative data on dose–response relationships. So, one
goal in the future may be the integration of ‘omics data into the risk characterisation of chemicals.
Based on an example from food toxicology, it was shown how ‘omics data could be used in risk
assessment and which way forward for their future role in risk assessment is possible. By using in silico
methods (QSAR), mutagenic and carcinogenic chemicals were identiﬁed among more than 800 heat-
induced processing contaminants and a priority list of compounds was established. Using this
approach, 3-monochloropropanediol (3-MCPD) was identiﬁed. A detailed analysis of the proteome and
transcriptome of 3-MCPD-treated rats identiﬁed molecular targets for 3-MCPD, e.g. related to glucose
utilisation and oxidative stress. The antioxidant protein DJ-1 was strongly deregulated at the protein
level in kidney, liver and testis, and giving new insights in the MOA of this relevant food contaminant.
These new results were recently taken up by EFSA in the course of the risk assessment of 3-MCPD,
showing that ‘omics data found its way into risk assessment in the MOA section. So far, there has been
only limited use of ‘omics techniques in standard toxicity tests performed to identify adverse effects,
because of existing limitations. However, by implementation of relevant MOA data into the AOP
concept, it will be possible to link MOA effects observed by ‘omics methods to adversity. Furthermore,
it will also be possible to develop appropriate in vitro test systems to predict adverse outcomes with
signiﬁcant evidence. Then, it may be possible to modulate the margin of exposure concept by
comparing relevant human in vitro ‘omics data together with biological endpoints (AOP data) with
human endogenic endpoints (metabolomics data, biomarker of exposure). In summary, new
techniques such as in silico methods (e.g. QSAR, PBPK modelling) as well as ‘omics data together with
endogenic biomarkers will fundamentally improve risk assessment in the future.
2.1.4. Integrating pharmacokinetics and pharmacodynamics in AOPs for next
generation risk assessments
Quantitative analysis and modelling of data is one of the most important aspects of risk analysis
and assessment. Relevant modelling activities are often divided into pharmacokinetics (PK; related to
exposure assessment) and pharmacodynamics (PD; related to dose–response) in a rather simplistic
way. We tend toward a fusion of the two disciplines into systems toxicology, at the point where they
meet. In any case, modelling has always been important for low-dose extrapolation, exposure route
adjustments or assessing the impact of interindividual variability. Yet, new challenges are emerging:
quantitative in vitro to in vivo extrapolation, high-throughput and high content data integration, and
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integration within the AOP framework. In response to the need for in vitro data integration and
extrapolation, pharmacokinetic modelling has deﬁnitely taken a physiological (PBPK) turn in the last
10 years. Models of drug distribution of chemicals in the animal and human body have dramatically
improved, but new models are now being developed to address the complexity of the new in vitro
systems. The zebraﬁsh model is usable for human and ecological risk assessments. A whole series of
pharmacokinetic models of in vitro systems is also being developed in ongoing projects such as EU-
ToxRisk. In parallel, the methods for fast simulations and calibration of complex models with
experimental data have also been considerably improved over the last decade. AOP models are also
being actively developed. Given their potential number and complexity, the best mathematical tools to
use are not precisely now known. For extrapolation purposes, systems toxicology models would
probably be favoured, being fundamentally mechanistic, like PBPK models. Yet, they can be extremely
complex and data hungry. Statistical models (such as linked non-linear regression relationships or
Bayesian networks) might be simpler to develop, but they may have more restricted applications. In
between, there is a whole range of pharmacodynamic models, such as the effect compartment model,
often used in pharmacology, but much less so in toxicology. Research is very active in those areas, and
it is likely that, for a quite while, the various approaches will co-exist. PK/PD modelling of the effects of
random mixtures of aromatase inhibitors on the dynamics of women’s menstrual cycles was assessed.
Using high-speed computer code, random exposures to millions of potential mixtures of 86 aromatase
inhibitors present both in the US EPA ToxCast and ExpoCast databases were simulated. A PK model of
intake and disposition of the chemicals was used to predict their internal concentration as a function of
time (up to 2 years). In vitro concentration–inhibition relationships for aromatase were collected from
ToxCast and corrected for cytotoxicity. The resulting total aromatase inhibition was input to a
mathematical model of the hormonal hypothalamus–pituitary–ovarian control of ovulation in women.
At aromatase inhibitor concentrations leading to over 10% inhibition of oestradiol synthesis, noticeable
(eventually reversible) effects on ovulation were predicted. Exposures to single chemicals never led to
such effects. However, a few per cent of the combined exposure scenarios were predicted to have
potential impacts on ovulation, and hence fertility. These results demonstrate the possibility to predict
large-scale mixture effects for endocrine disrupters with a predictive toxicology approach, suitable for
high-throughput ranking and risk assessment.
2.1.5. Modelling tools to assess risks related to cadmium exposure for workers
and consumers
This was a case study to provide a practical example of application of modelling tools to risk
assessment. Speciﬁcally, the French Agency Anses (Agence nationale de securite sanitaire de
l’alimentation, de l’environnement et du travail) was asked to revise the dietary toxicological reference
value (TRV) for cadmium and to propose cadmium maximum levels in fertilising materials and culture
media to control soil pollution and in turn the contamination of plants for food use.
For non-smokers, food is the main source of cadmium exposure for its high environmental
persistence and high rate of soil-to-plant transfer. Anses identiﬁed bone effects as the key effects and
used the 2011 and 2012 epidemiological studies by Engstr€om and colleagues (Engstr€om et al., 2011,
2012) as the key studies for setting a TRV. The no-observed-adverse-effect level (NOAEL) for this
effect for a population over 60 years of age corresponded to an internal dose of 0.5 lg cadmium/g
urinary creatinine. Based on a PBPK model (Kjellstr€om and Nordberg, 1978; Ruiz et al., 2010) that
included data on the variation of creatinine excretion as a function of both age and body weight, and
that related cadmium urinary concentrations to Cd oral concentrations, a tolerable daily intake (TDI) of
0.35 lg cadmium/kg body weight (bw) per day could be derived. The PBPK model also made it
possible to estimate the urinary cadmium excretion limit (cadmium health-based guidance value
(HBGV) in lg/g of creatinine as a function of age) not to be exceeded at any age to prevent
exceedance of the internal TRV at adulthood, i.e. 0.5 lg/g creatinine at 50 years of age (Bechaux
et al., 2014). Depending on the input of cadmium in soils (according to different scenarios of soil
fertilisation), a predictive model was drawn up for estimating the trend of cadmium contamination in
plants for human consumption over the following 99 years.
The construction of the model was carried out in two stages:
• Firstly, the transfer of cadmium from its input via fertilisers on agricultural soils to plant
produce (potato and wheat grain) was modelled. This part of the model was built on the basis
of a ‘mass-balance’ approach, taking into account: (i) all the routes of cadmium entry into the
agricultural soil (fertilising materials, atmospheric deposition, irrigation water); (ii) routes of
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cadmium release from the soil (food crops, leaching); (iii) variabilities; and also (iv) French
speciﬁcities along this transfer. This ﬁrst phase of the model made it possible to study the
cadmium contamination of agricultural soils and crops as well as the cadmium leached, as a
function of cadmium inputs via fertiliser materials and their agricultural practice in the next
99 years;
• In a second step, the transfer of cadmium through food from the plant produce to the
consumers was modelled to estimate the impact on consumer exposure. Simulations of various
fertilisation scenarios were run with an updated Anses model to predict changes in Cd
concentration in wheat grain and potatoes. The obtained variations of the cadmium
concentration in plants made it possible to estimate the impact on consumer cadmium
exposure.
So, the prepared model based on cadmium ﬂux is a predictive support to estimate cadmium levels
in the plants and in the ﬁnal related food products. The output data of the model allow derivation of
the adult and child consumer’s average chronic exposure and 95th percentile, as a function of the
projection time of the modelling (10, 20, 60, 99 years), in correlation with the study of the trend of
cadmium contamination in crops (wheat grain and potato) linked to fertilisation scenarios. It is also
feasible to estimate a possible percentage of excess of the TRV. These mathematical models (from
ﬁeld to fork) are useful tools to support the risk assessment and decision-making processes. Based on
such simulations, acceptable levels of cadmium pollution in fertilisers, soils and at the end food items
may be determined.
2.1.6. Predictive tools in the risk assessment of new proteins in genetically
modiﬁed organisms (GMOs): the case of coeliac disease
Coeliac disease (CD) is a disease of the small intestine characterised by ﬂattening of the intestinal
surface, resulting in a variety of clinical symptoms including malabsorption, failure to thrive, diarrhoea
and stomach ache. The disease is caused by an uncontrolled intestinal CD4 T-cell response to gluten
proteins in wheat (Triticum ssp.) and to the gluten-like hordeins and secalins in barley (Hordeum
vulgare) and rye (Secale cereale). Oat (Avena sativa) is generally considered safe for patients although
exceptions have been reported. The only available treatment is a life-long gluten-free diet including the
exclusion of all food products that contain wheat, barley and rye or gluten and gluten-like proteins
from these grains. CD has a strong genetic component as it is associated with particular immune
response genes, called HLA in man (Koning et al., 2015). Most CD patients express certain HLA-DQ-
molecules. HLA-DQ molecules are dimers of an alpha- (DQA1) and a beta- (DQB1) chain. As for all
HLA-molecules, HLA-DQ molecules bind short peptides and present these to T cells of the immune
system. The large majority of CD patients expresses HLA-DQ2.5 while the remainders are usually HLA-
DQ8 positive. In patients, but not in healthy individuals, pro-inﬂammatory gluten-speciﬁc CD4+ T cells
are present in the lamina propria of the affected duodenum. Importantly, these CD4+ T cells recognise
gluten peptides only when presented by the disease associated HLA-DQ molecules. In essence, in
patients with CD the immune system makes a mistake: the harmless gluten proteins in the food are
recognised as if derived from a pathogen, leading to a pro-inﬂammatory response as long as gluten is
consumed. Elimination of gluten from the diet constitutes an effective treatment as the T-cell
stimulatory gluten peptides are no longer present. Unfortunately, once a gluten-speciﬁc T-cell response
has developed, this results in immunological memory. Therefore, every subsequent exposure to gluten
will reactivate the gluten-reactive T cells and results in inﬂammation. A life-long gluten-free diet is so
required. T-cell epitopes derived from the a-, c- and x-gliadins as well as from the HMW and LMW
glutenins have been reported. In addition, T-cell epitopes in both hordeins and secalins have been
identiﬁed that are highly homologous or even similar to those found in wheat. A detailed knowledge of
these known disease-causative sequences in gluten allows the design of a speciﬁc strategy to identify
potential harmful sequences in other proteins. This strategy is presented in the EFSA guidance on
allergenicity assessment of GM plants (EFSA GMO Panel, 2017).
2.2. New approaches in exposure assessment
2.2.1. Human biomonitoring
The European Human Biomonitoring Initiative (HBM4EU, https://www.hbm4eu.eu/) follows an
innovative approach to generate the knowledge that policy makers need to improve policy in
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environment and health. The over-arching goal of HBM4EU is to generate new knowledge, to inform
the safe management of chemicals, and so protect human health in Europe (Ganzleben et al., 2017).
Human Biomonitoring (HBM) data supply information on the aggregate exposure from all sources and
by all pathways, serving as the basis to assess the risks from human exposure to chemicals. The
research programme is based on the policy needs and priority chemicals identiﬁed after consultation
with European and national policy makers. It builds upon existing knowledge from national and EU
monitoring and research programmes. HBM4EU consists of more than 110 partner organisations from
28 countries, 27 European countries plus Israel, and is organised around 16 work packages led by key
players of national HBM studies and research programmes. Major ﬁelds of activities are the science
policy transfer, HBM studies and research to elucidate the impact of exposure on health. Data
management under HBM4EU collects existing HBM data, currently fragmented in Europe. Exposure
data valid for the whole of Europe, the identiﬁcation of vulnerable or highly exposed subpopulations
and the analysis of spatial and temporal exposure trends are major goals of HBM4EU. HBM is also
considered to be key for addressing exposure to mixtures, as it reveals the extent and quality of
multiple chemicals exposures. These data also demonstrate the need to develop concepts for health
risk assessment beyond traditional single substance evaluation methods. Intensive communication with
policy makers from the state of planning on will ensure that HBM4EU results are used in the further
development and design of new chemicals policies, as well as in the evaluation of existing measures.
Among the recommendations for a better inclusion of HBM in risk assessment there are:
• the creation of awareness on capabilities of HBM at EU and national level;
• developing harmonised guidance for the use of HBM data;
• setting HBM HBGVs.
2.3. Holistic assessment of exposures to environmental and endogenous
oestrogens by internal dosimetrics
Exposure to oestrogenic compounds through the diet and environment is an ongoing public health
focus. This focus is based on a hypothesis that some endocrine-active compounds bind to oestrogen
receptors to a sufﬁcient degree to affect genomic signalling and so adversely impact normal endocrine
function in animals and humans that, over time, leads to a number of diseases. For example, extensive
research and risk assessment activity has centred on the potential for adverse effects from exposure to
the food contact-associated oestrogenic chemical, bisphenol A (BPA), especially during the perinatal
period. A large body of pharmacokinetic evidence from rodents, non-human primates and humans,
which includes exposures during early neonatal and adult life stages, has been incorporated into PBPK
models for BPA (Yang et al., 2015). Circulating concentrations of BPA in individuals with average and
high consumption of canned foods are consistently in the low picomolar range. The modelled outputs
for internal dosimetry from rodent and human models can also provide chemical-speciﬁc factors for
use in computing HBGVs from toxicological studies in rodents. In addition, the plausibility of oestrogen
receptor-mediated effects from BPA, based on measurements in serum and/or urine of BPA, dietary
oestrogens [genistein (GEN), daidzein (DDZ)] and endogenous hormones [oestrone (E1), oestradiol
(E2), oestriol (E3) and the fetal liver-derived oestetrol (E4)], was evaluated using mathematical
calculations of fractional receptor occupancy (FRO) and relative responses (RR) for activation of
oestrogen receptors (ERa and ERb) in the presence of serum binding proteins (sex hormone binding
globulin (SHBG) and albumin) in a cohort of pregnant women (Pande et al., 2019). These comparisons
were made to critically evaluate the hypothesis that serum BPA must contribute sufﬁcient added
activity to shift total oestrogenicity by a meaningful increment over normal intraindividual daily
variability to be considered important. The median FRO for BPA was ﬁve orders of magnitude lower
than E1, E2 or E3 and three orders of magnitude lower than E4, GEN or DDZ. Similarly, based on the
RR values, E3 was the most potent serum oestrogen during pregnancy (median RR values of 0.746
and 0.794 for ERa and ERb receptors, respectively). The median RR values for E2 were 0.243 for ERa
and 0.167 for ERb. The RR values for the remaining oestrogens were consistently less than 0.01.
Moreover, RR values were even lower for the dietary oestrogens, GEN and DDZ and BPA. Also, these
minor interactions with BPA were dwarfed by the intraday and interindividual variability in the activity
from endogenous oestrogens present in the pregnant women. Similarly, the receptor binding levels of
endogenous oestrogens in normally cycling non-pregnant women suggest that BPA interactions would
also be negligible. A consistent body of evidence comprising: (i) classical pharmacokinetic and PBPK
modelling approaches that indicate minimal internal exposures from realistic doses; and (ii) the
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implausibility of observable oestrogenic actions in ordinary pregnant women, reafﬁrms the conclusions
of most regulatory bodies world-wide that exposure to BPA resulting from approved food contact uses
is safe (US Food and Drug Administration, 2014; EFSA, 2015).
2.4. The exposome in practice
The identiﬁcation of hazardous environmental pollutants is complex, particularly in relation to
chronic, non-communicable diseases. The main contributors to this complexity are the diversity of
hazards that may exist, the typically low levels of environmental contaminants/pollutants, long latency
periods and largely unknown modes of action. The unravelling of environmental causes of disease is
also limited by the technical difﬁculties in deﬁning, and accurately measuring, exposures and by
considerable spatial, temporal and intraindividual variation. The complex and partially unknown
interaction with underlying genetic and other factors that modulate susceptibility and response to
environmental exposures further complicates the process of delineating and understanding
environmental hazards. To address such difﬁculties, the concept of the ‘exposome’ was proposed,
initially by Wild (2005), with more recent detailed development in relation to its application to
population-based studies (Wild, 2012). The original concept was expanded by others, particularly
Rappaport and Smith (2010), who functionalised the exposome in terms of chemicals detectable in
biospecimens. The exposome concept refers to the totality of exposures from a variety of sources
including, but not limited to, chemical agents, biological agents, radiation and psychosocial component
from conception onward, over a complete lifetime, and offers a conceptual leap in studying the role of
the environment in human disease (Rappaport and Smith, 2010; Wild, 2012; Vineis et al., 2017).
There are two broad interpretations of the exposome concept, and they are complementary. One,
called ‘top-down’, is mainly interested in identifying new causes of disease by an agnostic approach
based on ‘omic technologies, similar to that applied in genetics with the genome-wide association
study (GWAS) design. This approach is sometimes called an exposome-wide association study (EWAS),
and utilises tools such as metabolomics or adductomics to generate new hypotheses on disease
aetiology. The second general approach is called ‘bottom-up’ and starts with a set of exposures or
environmental compartments to determine the pathways or networks by which such exposures lead to
disease, i.e. which pathways/networks are perturbed. We have used the latter approach in the EU-
funded EXPOsOMICS project (Vineis et al., 2017), that was focused on air pollution and water
contamination. The experience of air pollution is particularly instructive. While in the 1970s and early
1980s air pollution was considered as a relatively marginal exposure in terms of attributable risks, the
most recent estimate is that it accounts for 7.6% of global deaths and 4.2% of global disability-
adjusted life years (DALYs) world-wide (Vineis and Fecht, 2018). The change in appreciation of the role
of air pollution has been mainly due to the reﬁnement of exposure assessment methods and the new
generations of longitudinal studies. Mechanistic evidence via ‘omic technologies is now rapidly
increasing, so lending credibility to previous epidemiological (‘black box’) associations (Vineis, 2018;
Vineis and Fecht, 2018). In the EXPOsOMICS project, a few priorities for research were selected, with
relevant practical implications for policy making and stakeholders: can our knowledge be consolidated
on the health effects of those two important exposures, air pollution and water contaminants,
reinforcing causal assessment? Can variation in exposures in a ﬁner way than with the standard tools
of epidemiology be detected? Can the effects of low and very low levels of exposure using ‘omic
biomarkers be detected? How can ‘omic measurements to study pollutant mixtures be exploited? Can
improved exposure assessment to calibrate estimates of risk and burden of disease be used? As a
result, developed methodologies for the validation of a set of ﬁve ‘omics measured in the same
subjects (for a total number of more than 2,000 individuals), and statistical tools to allow the analysis
of very complex data sets were developed. Compared with air pollution, much less information is
known about other environmental contaminants, some of which are widespread and pervasive, so
suggesting the need for the same rigorous methods as those applied to air pollution.
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2.5. Integrating new tools and new approaches in exposure assessment –
examples
2.5.1. Integrated safety assessment of genetically modiﬁed food/feed: the
experience from the EU projects GRACE and G-TwYST
The application of the classical tools developed for the risk assessment of chemicals to the
evaluation of risk derived from GM plants has been very controversially discussed, particularly as
regards animal studies on whole food and feed. The EFSA GMO Panel indicated the possibility to use a
90-day study on whole food/feed based on the OECD Test Guideline 408 (OECD TG 408, 1998) in case
a speciﬁc hypothesis was identiﬁed in the course of the preliminary analysis of the GMO (e.g.
comparative assessment of the compositional and agronomic-phenotypic characteristics of the GM
crop) (EFSA GMO Panel, 2011). EFSA’s Scientiﬁc Committee developed principles and guidance for the
establishment of protocols for 90-day whole food/feed studies in rodents, adapting the existing OECD
Test Guideline 408 to the peculiar test item ‘food/feed’ (EFSA Scientiﬁc Committee, 2011). Regulation
(EU) No 503/20132 on applications for EU market authorisation of GM food and feed in accordance
with Regulation (EC) 1829/20033 made mandatory the 90-day rodent feeding study on the whole GM
food/feed for single transformation events, even in the absence of hypotheses. In a later explanatory
statement (EFSA, 2014), EFSA provided further instructions on how to apply the general principles
described in the EFSA Scientiﬁc Committee Guidance for the study design and analysis of such 90-day
studies for GMO risk assessment and described two possible scenarios (scenario 1: a speciﬁc
hypothesis is available, i.e. the preceding analyses have identiﬁed a potential risk(s); scenario 2: no
speciﬁc hypothesis is available, i.e. no potential risk has been identiﬁed). Upon request from the
European Commission, EFSA also prepared a scientiﬁc report that would support the future
establishment of protocols for chronic toxicity and/or carcinogenicity studies in rodents with whole
food/feed (EFSA, 2013). Two EU-funded projects, GRACE (GMO Risk Assessment and Communication
of Evidence) and G-TwYST (Genetically modiﬁed plants Two Year Safety Testing), performed animal
feeding trials and alternative in vitro methods with two different GM maize varieties to determine how
suitable they are and what useful scientiﬁc information they provide for the health risk assessment of
GM food and feed. Subchronic and chronic toxicity as well as carcinogenicity testing in rats was
conducted based on OECD Test Guidelines for the testing of chemicals and on the above-mentioned
EFSA documents. Under the GRACE project, 90-day feeding trials as well as a 1-year feeding trial with
two GM MON810 maize varieties and several different near-isogenic varieties were performed
(Zeljenkova et al., 2014, 2016; Schmidt et al., 2017). Moreover, ‘omics as well as in vitro (cell culture)
approaches were performed to evaluate their possible added value in the overall risk assessment of
GM crops (van Dijk et al., 2014; Sharbati et al., 2017). Based on the EFSA explanatory statement, the
OECD Test Guideline 453 as well as the scientiﬁc report by EFSA on the applicability of the OECD Test
Guideline 453 to whole food/feed testing (EFSA, 2013) and taking into account possible concerns
raised by a publication on the long-term toxicity of the GM maize NK603 (Seralini et al., 2012), the
G-TwYST consortium performed two 90-day feeding trials as well as a combined 2-year chronic
toxicity/carcinogenicity study in rats with the GM maize NK603. The main ﬁndings of the different
experimental approaches in the GRACE and G-TwYST projects were presented. In these projects, it
was concluded that rodent feeding trials do not provide added value to the risk assessment of GM
crops in the case that relevant changes and/or speciﬁc hazards have not been identiﬁed in preceding
analyses. Based on the experience gained in these two EU-funded research projects, it was highlighted
that relevant aspects of the study design include the choice of the rodent strain, the incorporation rate
of the GM crop to be tested and consideration of cage effects. A new development in the statistical
analysis of the data obtained in these rodent feeding trials included the equivalence testing, in addition
to the difference testing, to support the interpretation of differences between animals given the GM
crop and controls. An ‘omics technique (metabolomics) was used to further characterise the
composition of the GM crop; this technique was considered promising, but needs further discussion as
regards its integration into the risk assessment process. In vitro techniques to investigate effects of the
GM crop on the intestine and on the immune system did not show changes in rats given the GM crops
2 Commission Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically modiﬁed food and
feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and amending
Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, pp. 1–48.
3 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, pp. 1–23.
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as compared with concurrent controls. However, in the absence of a positive control, it is difﬁcult to
fully set out their relevance in this context. In the above-mentioned projects, attention was given to
communication, transparency, engagement of stakeholders and Responsible Research and Innovation
(RRI) principles.
2.5.2. CLARITY-BPA Project: Core NCTR/NTP study on BPA and lesson learnt on
integrating regulatory and academic investigations in hazard assessments
by the US National Toxicology Program
One of the challenges faced in the regulatory setting is the integration of data from investigative
academic studies with those Good Laboratory Practice (GLP) studies conducted according to test
guidelines for submission to regulatory agencies for making risk assessment decisions. The way in
which these different types of studies are conducted and reported is a challenge when trying to
integrate different data streams. These issues are often related to exposure levels, study design and
conduct, chemical purity, statistical power, reporting of study details, selective reporting of data, risk of
bias, directness of end-point measures to a health outcome, and data reporting transparency. One
such a case is that of BPA. BPA is a chemical produced in large quantities for use primarily in the
production of polycarbonate plastics and epoxy resins, that are used as lacquers to coat metal
products such as food cans, bottle tops and water supply pipes. Human exposure to BPA is
widespread, with 93% of Americans 6 years and older having detectable levels of BPA in their urine.
The health impact of low-level exposure to BPA is a topic of considerable debate world-wide. On the
one side a few GLP- and guideline-compliant studies support BPA safety at current exposure levels, on
the other side hundreds of smaller scale research studies have indicated possible low-dose effects of
this substance. In two subsequent presentations, the experience with the research programme
developed by the US National Institute of Environmental Health and Safety (NIEHS), the National
Toxicology Programme (NTP), and the Food and Drug Administration (FDA), the so-called Consortium
Linking Academic and Regulatory Insights on BPA Toxicity (CLARITY-BPA; Schug et al., 2013) was
presented. The CLARITY-BPA research programme was initiated with the aim of ﬁlling the gap between
guideline-compliant research and hypothesis-based research projects on the toxicity of BPA (Birnbaum
et al., 2013). This project investigated a broader range of potential health effects from exposure to
BPA especially in the low-dose range that could inform regulatory decision making.
The CLARITY-BPA research programme has two components: (i) A ‘core’ modiﬁed guideline-
compliant chronic study conducted at FDA’s National Center for Toxicological Research (NCTR)
according to FDA GLP regulations (2-year perinatal only or chronic BPA exposure, including perinatal);
and (ii) CLARITY-BPA grantee studies of various health endpoints, conducted by NIEHS–funded
researchers at 14 academic institutions using tissues and animals born to the same pregnant rats and
exposed under identical conditions as the core GLP study (Heindel et al., 2015).
In the core study, the toxicity of BPA administered by oral gavage from gestation day 6 until labour
and then directly to pups by daily gavage from post-natal day 1 was examined in Sprague–Dawley
rats. Study materials were monitored for background BPA levels throughout. A wide range of BPA
doses was used ranging from as close as feasible to estimated human exposure levels to a reasonable
margin of exposure (2.5, 25, 250, 2,500, and 25,000 lg/kg bw per day). Because many of the
reported effects of BPA are associated with oestrogen-signalling pathways, two doses (0.05 and
0.5 lg/kg bw per day) of ethinyl oestradiol (EE2) were also included to monitor the response of the
model to an oestrogen. In addition to animals dosed daily throughout the study (continuous-dose
arm), a stop-dose study arm was included for the BPA doses only, with animals dosed until post-natal
day 21 and then held without further treatment until termination, to assess any effects that were due
to early exposure. In both study arms, animals were terminated at 1 year (interim) and 2 years
(terminal). Statistical comparisons were conducted within sex, study arm, and sacriﬁce time and BPA
and EE2 groups were analysed separately. Data collected included survival, body weights, litter
parameters, age at vaginal opening, vaginal cytology, including an assessment of the onset of aberrant
cycles, clinical chemistry (interim sacriﬁce only), sperm parameters (interim sacriﬁce only), organ
weights (interim sacriﬁce only) and histopathology (both interim and terminal sacriﬁces). The grantee
studies assessed a range of molecular, structural and functional endpoints that are not typically
assessed in guideline-compliant studies (Heindel et al., 2015). As the safety assessment of BPA is
outside the scope of this paper, for the results of the core and grantee studies the reader should
consult the NTP website (https://manticore.niehs.nih.gov/cebssearch/program/CLARITY-BPA).
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The key strengths of this consortium approach included: (i) the identical BPA exposure conditions
used for both components of the consortium, which were provided at the same facility (NCTR); (ii)
blinding of the core study samples received by the academic grantees, therefore minimising the
potential risk of bias; and (iii) the development of an a priori list of endpoints to be collected per study
and the requirement that all data be deposited in a private workspace in the NTP’s database before
decoding. This allowed for conﬁdential data acquisition and blinded deposition of data and also
ensured that subsequent public access to data had no bias in end-point data acquisition. There were
limitations to this approach though. Academic investigators were limited to using a speciﬁc shared
design and model that may not have been optimal for the speciﬁc endpoints proposed. Sample
acquisition was centralised and coordinated so highly specialised sample preparation or animal
handling procedures required additional coordination, training and resources. Thirdly the scheme for
peer review and selection of grantee proposals followed traditional National Institutes of Health (NIH)
peer review procedures such that guidance was more general in nature and submitted proposals were
not speciﬁcally aligned to address speciﬁc regulatory needs, but rather hypothesis generated research
questions. Looking forward, a key lesson learnt from the CLARITY-BPA programme is that, for future
initiatives, a less resource intensive approach is needed with much more targeted and integrated
problem formulation and consortia development phase more direct communication between what the
regulatory scientists need to make decisions and what the academic scientists can provide. This would
result in closer alignment between the identiﬁed regulatory data gaps and the design of the studies
and would maximise the utility of such collaborative programmes, while decreasing their costs.
2.5.3. Setting a health-based guidance value using epidemiological studies
In chemical risk assessment, the use of benchmark dose (BMD) for deriving a HBGV is increasingly
being preferred over use of a single point estimate, such as the traditional NOAEL. In line with this
development EFSA’s Scientiﬁc Committee (EFSA Scientiﬁc Committee, 2017) recommends that scientiﬁc
panels should apply the BMD when setting HBGV. The use of BMD for human observational studies has
been partly hampered by how ﬁndings from epidemiological studies are conventionally reported,
highlighting the need for more dialogue between risk assessors and epidemiologists. More importantly,
there is currently no consensus on how to derive BMD for human studies as the BMD methodology has
mostly been developed for use in controlled studies in experimental animals. Although the same
principles generally apply for human studies, existing guidance may not always be directly applicable.
For example, in the updated EFSA guidance on BMD, model averaging based on a default set of pre-
selected models is recommended. However, the recommended models do not include linear or other
polynomial models. This may be logical for animal studies in which there are well deﬁned unexposed
controls (zero exposure) and the doses used often cover > 100 differences in exposure (making a
linear response over the full exposure range highly unlikely). For human studies the observed exposure
range is, in contrast, usually much narrower and the dose–response is often approximate linear. In
addition, in observational settings ‘unexposed individuals’ (zero exposure) usually do not exist, making
the reference point highly dependent on the study population and how it is selected. Furthermore, the
high variability observed in human studies and the use of biomarker concentrations to assess exposure
creates several additional challenges when deriving HBGV, and varying sample size the use of lower
bound benchmark doses (BMDLs) for human data needs some careful considerations. In conclusion,
there are no major obstacles for using human data to derive HBGV. BMD analyses can easily be
performed, but existing conventions may not be directly applicable, and more work is needed (as has
been carried out for animal data).
3. Conclusions and recommendations
A shift from the current risk assessment paradigm largely relying on animal studies to a more
holistic approach is possible and desirable. Such a shift would be based on NAMs offering a better
understanding of mechanisms leading to adverse effects and more accurate predictions of biological
responses, helping to establish causality and waiving the use of animal studies. This would be
integrated by novel approaches and tools in exposure and epidemiological sciences. Ultimately, this
holistic approach would improve human health assessment while reducing animal testing. Envisaged
by NASEM since 2007 and proposed in the EU in a SCHER/SCENIHR/SCCS report in 2013, such a
change in human health risk assessment paradigm can already beneﬁt from the availability of
scientiﬁcally and technically robust tools and comprehensive data sets. Overall, this shift would help to
optimise the way risk assessment is performed by both accelerating risk assessment pace and
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embracing experimental models of greater human relevance, while addressing societal concerns about
animal experimentation.
To support the paradigm shift to a holistic approach, efforts are needed, in the ﬁrst instance, to
promote the use of mechanism-based test systems, exploring molecular initiating events and early key
events complementing or replacing experimental animals tests designed to show adverse effects. This
is considered to be pivotal to support the understanding of biological pathways and would ultimately
enable more accurate predictions of biological responses to single or multiple stressors and help to
establish causality of effects. However, human-relevant in vitro assays, alternative models (e.g.
zebraﬁsh) and predictive modelling should be further developed and validated.
Efforts should be made to integrate NAMs with existing in vivo data matrices into existing AOPs but
also to support the development of new ones. This would allow risk assessors to use AOPs informed
approaches, to make sensible use of all available data, and to enhance conﬁdence on the mechanistic
understanding underlying a ‘regulatory’ adverse outcome. This could be achieved by fostering the
causal link between molecular and cellular effects of substances, and their effects at the level of
organs, organisms and populations.
The advances in new exposure and epidemiology sciences, as well as the availability of human
biomonitoring data set should be considered, and strategies should be developed for their
incorporation into a holistic exposure assessment. The use of already available data in the current risk
assessment faces challenges. A rethinking of how to conduct and use epidemiological studies/data is
also needed. These should be designed to be part of the path being incorporated in the AOP
framework and used to consolidate human adverse outcomes in the testing paradigm.
Also relevant is the development of methodologies and guidance to reﬁne the prediction of blood
and tissue concentrations from exposure through TK or PBTK modelling. Conversely, in vitro-derived
potency information needs to be converted into dosimetry information that, in turn, can be translated
into corresponding external doses using in vitro–in vivo extrapolation (IVIVE) tools.
Data gathering, organisation, curation and use are perceived as priorities in this context. The
development of databases and softwares for high-throughput screening (HTS) and high content image
analysis (HCA) is needed to facilitate international harmonisation and promote the use of NAMs and
the large amount of data produced by these technologies.
Strategies are required for re-engineering already available data matrices and making them
accessible, readable, interpretable, usable and integrable with the new data streams. To facilitate and
standardise a transparent risk assessment, electronic submission of toxicological, exposure and
epidemiological raw data should be promoted by creating a digital network of relevant information.
The successful implementation of NAMs and other new developments in future risk assessment will
necessitate cooperation of academia, risk assessors and international bodies such as the OECD, and
the identiﬁcation of these areas as high research priorities for long-term and ﬂexible funding at the
European level, this being supported by an effective dialogue between funding bodies, academia and
risk assessors.
Overall, the recommendations from this symposium can be summarised as follows:
• bridging of the gap between traditional risk assessment methodologies, the assessment of
non-standard endpoints and new approach methodologies to enable a shift in the risk
assessment paradigm over the coming years;
• promoting the regulatory acceptance of reliable and predictive NAMs;
• provision of political support and long-term research programmes that are ﬁt for purpose and
that provide long-term and ﬂexible research funding to make robust science available to
accelerate the pace of risk assessment;
• promoting education and dedicated training programmes that engage risk assessment bodies,
academia and relevant stakeholders to build the necessary capacity in terms of
multidisciplinary expertise.
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Human health risk assessment
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MRA mixture risk assessment
NAM new approach method
NASEM National Academies of Sciences, Engineering and Medicine
NCTR National Center for Toxicological Research
NIEHS National Institute of Environmental Health and Safety
NIH National Institutes of Health
NOAEL no-observed-adverse-effect-level
NTP National Toxicology Programme
OECD Organisation for Economic Co-operation and Development
PBPK physiologically based pharmacokinetic
PBTK physiologically based toxicokinetic
PCB polychlorinated biphenyl
PD pharmacodynamics
PK pharmacokinetics l
POP persistent organic pollutant
QSAR quantitative structure–activity relationship
RDT repeated dose systemic toxicity
RR relative responses
RRI Responsible Research and Innovation
SHBG sex hormone binding globulin
TK toxicokinetic
TDI tolerable daily intake
TRV toxicological reference value
WHO World Health Organization
Human health risk assessment
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